Key Drivers
- Strong Margins
- Cash Generation
- Balance-Sheet Risk
AIAI Summary
Novartis is shifting from a post-patent-cliff recovery story to a test of whether Kisqali/Kesimpta/Scemblix/Pluvicto and newer launches can durably offset Entresto erosion, but with margins slipping, liquidity weaker, and the stock still not confirming the beat, upside now depends on second-half growth proving real and the shares reclaiming the 154–156 resistance zone rather than losing 149.56 support.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Cash Generation
- •Balance-Sheet Risk
NVS remains highly profitable and cash-generative, but rising leverage, weakening liquidity, and an already full valuation temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Weak momentum
NVS has drifted lower over the last month, with sellers in control while $150-$151 support is tested and a reclaim of $154-$156 is needed to turn momentum positive.
Hit a high near $159.85 on 2026-07-28, then failed to hold and rolled into a lower-high/lower-low pattern
Sentiment & News
Key News Insights:
- •Growth rebound
- •Pipeline progress
- •Entresto pressure
Novartis regained sales growth and beat earnings expectations on strong newer drug momentum, but Entresto patent erosion and generic competition remain key headwinds.
The stock's outlook is constructive as new launches and pipeline wins support revenue, though ongoing generic erosion may cap upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings